Wall Street analysts expect that Pfizer Inc. (NYSE:PFE) will announce earnings of $0.56 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Pfizer’s earnings. The highest EPS estimate is $0.57 and the lowest is $0.53. Pfizer posted earnings of $0.47 per share in the same quarter last year, which suggests a positive year over year growth rate of 19.1%. The business is scheduled to announce its next earnings report before the market opens on Tuesday, January 30th.
According to Zacks, analysts expect that Pfizer will report full-year earnings of $2.59 per share for the current fiscal year, with EPS estimates ranging from $2.57 to $2.60. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.74 per share, with EPS estimates ranging from $2.66 to $2.80. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Pfizer.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the prior year, the company posted $0.61 EPS. The company’s quarterly revenue was up .9% on a year-over-year basis.
Several equities analysts have recently commented on the company. Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a research note on Friday. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Friday, December 15th. UBS Group set a $40.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Finally, Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $38.88.
Pfizer (NYSE:PFE) opened at $36.86 on Monday. Pfizer has a 12 month low of $30.90 and a 12 month high of $37.35. The company has a market capitalization of $219,710.00, a price-to-earnings ratio of 22.61, a PEG ratio of 2.46 and a beta of 1.01. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer announced that its Board of Directors has authorized a stock buyback program on Monday, December 18th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Thursday, February 1st. This represents a $1.36 annualized dividend and a yield of 3.69%. Pfizer’s dividend payout ratio is presently 78.53%.
In other Pfizer news, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at approximately $1,740,918.41. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Shine Investment Advisory Services Inc. purchased a new position in shares of Pfizer in the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware purchased a new position in shares of Pfizer in the 2nd quarter valued at about $103,000. D. Scott Neal Inc. increased its holdings in shares of Pfizer by 19.3% in the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the last quarter. Herndon Capital Management LLC purchased a new position in shares of Pfizer in the 2nd quarter valued at about $120,000. Finally, Americafirst Capital Management LLC purchased a new position in shares of Pfizer in the 3rd quarter valued at about $127,000. Institutional investors own 69.75% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/1798192-2/1798192.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.